GlassScriptPhysician profile
John J Bodkin
NPI 1609831536
$2,209.41
in general payments reported to CMS, 2019-2025
32 companies · $105 in 2025
The $105 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,034 · 2020: $375 · 2021: $535 · 2022: $80.76 · 2023: $46.97 · 2024: $32.22 · 2025: $105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $116 · Education: $68.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $116.34 |
| Education | $68.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $340.61 | 2019-2025 | |
| Novo Nordisk INC | $232.14 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $213.84 | 2019-2023 | Lokelma |
| Amarin Pharma, INC. | $183.89 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $176.04 | 2021 | |
| Lilly USA, LLC | $138.38 | 2019-2021 | |
| Dexcom, INC. | $130.10 | 2021-2025 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $119.68 | 2019 | |
| Medtronic USA, INC. | $93.12 | 2020 | |
| Pfizer INC. | $70.50 | 2019-2021 | |
| Medtronic, INC. | $58.38 | 2021 | |
| Novartis Pharmaceuticals Corporation | $45.34 | 2019-2020 | |
| Amgen INC. | $44.76 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $42.40 | 2019-2020 | |
| Abbvie INC. | $38.90 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $27.81 | 2019 | |
| Urovant Sciences INC | $25.21 | 2022 | |
| Esperion Therapeutics, INC. | $24.91 | 2020 | |
| Radius Health, INC. | $20.09 | 2021 | |
| Allergan, INC. | $19.93 | 2020 | |
| Sanofi-Aventis U.S. LLC | $18.27 | 2021 | |
| Eisai INC. | $16.52 | 2020 | |
| Olympus America INC. | $15.78 | 2023 | Itind System |
| Genentech USA, INC. | $13.42 | 2019 | |
| Corcept Therapeutics | $13.03 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.82 | 2019 | |
| Glaxosmithkline, LLC. | $12.76 | 2020 | |
| Daiichi Sankyo INC. | $12.58 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $12.55 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.32 | 2019 | |
| Boston Scientific Corporation | $12.26 | 2019 | |
| Gilead Sciences, INC. | $11.07 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Bodkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.